نتایج جستجو برای: antiher2
تعداد نتایج: 27 فیلتر نتایج به سال:
Gradilone et al. [1] recently published a study addressing the prognostic and predictive value of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) and its relation to drug resistance molecular profile and stemness markers. We know that CTCs are highly relevant to the study of the biology of the metastatic process. The detection and enumeration of CTCs has been shown to be a usef...
Correspondence to Professor Andres Cervantes; [email protected] MUTATIONAL SIGNATURES WITH POTENTIAL THERAPEUTIC INTEREST IN OESOPHAGEAL ADENOCARCINOMA A consortium on clinical and molecular stratification on oesophageal adenocarcinoma established in Britain has recently published in Nature Genetics, a whole-genomic sequencing analysis of more than 100 samples. Interestingly, they describe...
Approximately one in four breast cancers is driven by amplification of the receptor tyrosine kinase HER2 (ERBB2). HER2 signals through oncogenic pathways, such as the phosphatidylinositol-3-kinase (PI3K)-Akt pathway. Blockade of HER2 with FDA-approved drugs such as trastuzumab, lapatinib, and pertuzumab has changed the natural history of HER2-positive (HER2+) breast cancers and improved patient...
The availability of the anti-HER2 monoclonal antibody, trastuzumab (Herceptin) has transformed the outcome of a subgroup of patients with breast cancer that previously had a poor prognosis, i.e., those with HER2positive disease [1]. Although HER2 gene amplification/ overexpression is necessary for breast cancer patients to receive trastuzumab, more than 50% of patients positive for this biomark...
Inhibition of epidermal growth factor receptor (EGFR) signaling is a promising treatment strategy for malignant tumors. In this study, we evaluated the effectiveness of Tyrphostin AG1478, a potent and specific inhibitor of EGFR tyrosine kinase, on the growth, apoptosis and invasion of breast cancer cells. Western blotting demonstrated that AG1478 inhibited the phosphorylation of EGFR, ERK1/2 an...
HER2þ breast cancer is currently treated with chemotherapy plus anti-HER2 inhibitors. Many patients do not respond or relapsewith aggressivemetastatic disease. Therefore, there is an urgent need for new therapeutics that can target HER2þ breast cancer and potentiate the effect of anti-HER2 inhibitors, in particular those that can target tumor-initiating cells (TIC). Here, we show that MMTV-Her2...
Over the past few years, nuclear medicine has undergone impressive growth with the development of positron emission tomography (PET), especially using 18Ffluoro-deoxy-glucose (18FDG), and new approaches in targeted radionuclide therapy. These developments pave the way for personalized medicine by offering practical solutions, especially in oncology, neurology, and cardiology. Novel radiopharmac...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید